ClinicalTrials.gg
CompletedNCT03467100Updated Jul 22, 2019

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

A Phase 1 interventional study of XEN901 and Inert Ingredients Oral Product in Healthy Volunteers, sponsored by Xenon Pharmaceuticals Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-22.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The XEN901 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics (PK) of both single ascending doses (SAD) and multiple ascending doses (MAD) of XEN901 in healthy subjects. It is estimated there will be approximately 64 subjects in the planned SAD and MAD cohorts.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy male or females aged between 18 and 55 years inclusive with a (BMI) between 18.5 and 32.0 kg/m2
  • Must agree to use effective methods of , if applicable
  • Able to swallow capsules
  • Able to provide written, personally signed and dated Form

Key Exclusion Criteria:

  • Any history of seizures
  • Any current and relevant history of significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk, affect clinical or laboratory results, or the subject's ability to participate in the study
  • Answering "yes" to any of the questions within the Columbia Suicide Severity Rating Scale
  • Mental incapacity or language barriers precluding adequate understanding, cooperation, and compliance with the study
  • No prescription or over-the-counter (OTC) medications (except hormonal contraception), herbal or dietary supplements OTC medications 14 days prior to dosing to study end
  • No smoking 60 days prior to dosing to study end
  • Any abnormalities in vital signs, , physical exam, or laboratory evaluations
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    XEN901

    Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort

    Drug: XEN901

  • Placebo comparator
    Placebo

    Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort

    Drug: Inert Ingredients Oral Product

Interventions

  • DrugXEN901

    Capsule filled with XEN901

  • DrugInert Ingredients Oral Product

    Placebo capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) as assessed by CTCAE v4.03

    To assess AEs as a criteria of safety and tolerability

    Time frame: From screening (28 days prior to Day 1) through to 30 days post-final dose

  2. Resting 12-lead electrocardiogram (ECG)

    To assess 12-lead ECG intervals (PR, QRS, QTcF, RR) as a criteria of safety and tolerability

    Time frame: At screening (28 days prior to Day 1) through to 7 days post-final dose

  3. Number of participants with vital sign abnormalities

    To assess vital signs as a criteria of safety and tolerability

    Time frame: At screening (28 days prior to Day 1) through to 7 days post-final dose

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Cmax is the maximum observed plasma concentration in ng/mL

    Time frame: Day 1 predose through to 7 days post-final dose

  2. Time to the Maximum Observed Plasma Concentration (Tmax)

    Tmax is the time in hours to reach Cmax following dosing

    Time frame: Day 1 predose through to 7 days post-final dose

  3. Terminal elimination half-life (t1/2)

    The time in hours required for the plasma level of the study drug to decrease by one-half during the terminal elimination phase

    Time frame: Day 1 predose through to 7 days post-final dose

  4. Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC0-last)

    The area under the plasma concentration-time curve \[in ng.h/mL\] from time zero to the time corresponding to the last quantifiable plasma concentration

    Time frame: Day 1 predose through to 7 days post-final dose

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Dec 2018, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 15, 2018
StartActual
Feb 19, 2018
Primary completionActual
Dec 19, 2018
CompletionActual
Dec 19, 2018
Last update
Jul 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03467100
Responsible party
Sponsor
First posted
Mar 15, 2018
Start date
Feb 19, 2018
Primary completion
Dec 19, 2018
Completion
Dec 19, 2018
Last update
Jul 22, 2019

Study contacts

Gregory Beatch, PhD
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zandatrigine

Start the discussion